Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

March 21, 2022

Study Completion Date

July 18, 2022

Conditions
Moderate to Severe Asthma
Interventions
DRUG

Tezepelumab

210 mg SC injection Q4W.

DRUG

Placebo

SC injection Q4W.

Trial Locations (15)

33133

Research Site, Miami

43617

Research Site, Toledo

45406

Research Site, Dayton

53228

Research Site, Milwaukee

65203

Research Site, Columbia

73034

Research Site, Edmond

73120

Research Site, Oklahoma City

75225

Research Site, Dallas

75708

Research Site, Tyler

76712

Research Site, Waco

78229

Research Site, San Antonio

84107

Research Site, Salt Lake City

92647

Research Site, Huntington Beach

93301

Research Site, Bakersfield

08225

Research Site, Northfield

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

AstraZeneca

INDUSTRY